Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

News & Events

Research into innovative treatments for asthma and antibiotic-resistant infections fuelled by Stan Perron Charitable Foundation grants

New funding from the Stan Perron Charitable Foundation will support research into innovative treatments for antibiotic-resistant infections and asthma in children, led by Wal-yan Respiratory Research Centre researchers. 

News & Events

International clinical trial reduced lung inflammation in young kids with cystic fibrosis

Promising results from an Australian-led clinical trial could drastically change the way we care for young children with cystic fibrosis (CF).

News & Events

Four The Kids researchers in running for West Australian of the Year Awards

Four outstanding The Kids Research Institute Australia researchers, including Institute Director, Professor Jonathan Carapetis AM, have been named finalists in the 2021 Western Australian of the Year Awards.

News & Events

The Kids researchers named as finalists in 2021 Premier’s Science Awards

Four The Kids Research Institute Australia researchers – working across diverse fields including paediatric anaesthesia, bioinformatics, ear health, and the health impacts of biodiesel exhaust – have been named as finalists in the 2021 Premier’s Science Awards.

News & Events

The Kids Research Institute Australia researchers take out prestigious Premier’s Science Awards

Three outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.

News & Events

Community engagement vital in battle against antimicrobial resistance: Wal-yan Centre to establish reference group

The Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern. 

Research

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial

Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries. 

Research

The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut-lung axis

In cystic fibrosis, gastrointestinal dysfunction and lower airway infection occur early and are independently associated with poorer outcomes in childhood. This study aimed to define the relationship between the microbiota at each niche during the first 2 years of life, its association with growth and airway inflammation, and explanatory features in the metabolome. 

Research

Normal values of respiratory oscillometry in South African children and adolescents

Noninvasive measurement of respiratory impedance by oscillometry can be used in young children aged from 3 years and those unable to perform forced respiratory manoeuvres. It can discriminate between healthy children and those with respiratory disease. However, its clinical application is limited by the lack of reference data for African paediatric populations. The aim of the present study was to develop reference equations for oscillometry outcomes in South African children and adolescents.

Research

Change in health outcomes for First Nations children with chronic wet cough: rationale and study protocol for a multi-centre implementation science study

In children, chronic wet cough may be a sign of underlying lung disease, including protracted bacterial bronchitis (PBB) and bronchiectasis. Chronic (> 4 weeks in duration) wet cough (without indicators pointing to alternative causes) that responds to antibiotic treatment is diagnostic of PBB. Timely recognition and management of PBB can prevent disease progression to irreversible bronchiectasis with lifelong consequences. However, detection and management require timely health-seeking by carers and effective management by clinicians.